Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc (NQ: MNPR )

0.7348 -0.0152 (-2.03%)
Streaming Delayed Price Updated: 11:34 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Monopar Therapeutics Inc

< Previous 1 2 Next >
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual... 
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Provides Encouraging Camsirubicin Clinical Data Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Participate in the Radiopharma Forum by the Lake 2023
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
Camsirubicin Phase 1b Dose­Escalation Trial Enrolling 5th Dose­Level Cohort (650 mg/m2) MNPR-101 RIT Shows Promising Imaging and Therapeutic Preclinical Study Results 
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Present at the Jefferies Radiopharma Innovation Summit
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar to Present at the 35th Annual Roth Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial
From Monopar Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.